Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
On Sunday, Exact Sciences Corp EXAS reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion.
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning.
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today.
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
Editor's note: The headline of this story was updated to correct an error related to the reported day of the week.
Why Is Exact Sciences Stock Trading Higher On Monday?
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase.
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
Exact Sciences presents new positive evidence backing the development of an MCED test.
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for a year or more. Despite its long history of losses, the company has comfortable liquidity cushions and will not need to raise cash to continue its normal operations.
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.
